Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
US Army
Johnson and Johnson
Baxter
Chinese Patent Office
Fish and Richardson

Generated: July 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,476,284

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,476,284
Title:Inhibitors of Bruton's tyrosine kinase
Abstract: Disclosed herein are compounds, including compounds having the Formula (A) ##STR00001## where A, R1, R2, R3, and R4 are as defined in the specification, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:13/328,718
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,476,284
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,476,284
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 8,476,284

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA ➤ Sign Up
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MARGINAL ZONE LYMPHOMA ➤ Sign Up
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
US Army
Teva
UBS
Boehringer Ingelheim
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.